FOXP3 and neoplasm: Taken together, these findings suggest that colon cancer patients may be divided into two groups based on the frequency of CD39+ intratumoral Treg and that patients with a high frequency of CD39-expressing Treg in the tumor may also have larger numbers of effector Treg, with a more activated phenotype driven by high Foxp3 expression.